TGF Beta Receptor Type 1 Pipeline Review, H2 2019
Summary
TGF Beta Receptor Type 1 Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30 pipeline Target constitutes close to 18 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report TGF Beta Receptor Type 1 Pipeline Review, H2 2019, outlays comprehensive information on the TGF Beta Receptor Type 1 Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
TGF Beta Receptor Type 1 Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30 Transforming growth factor beta receptor I is a TGF beta receptor encoded by TGFBR1 gene. It is involved in physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGFbetaregulated genes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 9 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Central Nervous System, Immunology, Musculoskeletal Disorders and Toxicology which include indications Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, NonSmall Cell Lung Cancer, Solid Tumor, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Metastatic Breast Cancer, Pulmonary Fibrosis, Sarcomas, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Androgenic Alopecia, Bladder Cancer, Bone Metastasis, Breast Cancer, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Degenerative Disc Disease, Fallopian Tube Cancer, Gastric Cancer, Glioblastoma Multiforme GBM, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Inflammatory Bowel Disease, Keloids, Liver Fibrosis, Lung Cancer, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Metastatic Melanoma, Metastatic Transitional Urothelial Tract Cancer, Multiple Myeloma Kahler Disease, Oral Mucositis, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Prostate Cancer, Radiodermatitis, Rectal Cancer, Recurrent Glioblastoma Multiforme GBM, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar, Systemic Sclerosis Scleroderma, Transitional Cell Carcinoma Urothelial Cell Carcinoma, TripleNegative Breast Cancer TNBC, Ureter Cancer, Urethral Cancer, Uterine Cancer and Wounds.
Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Scope
The report provides a snapshot of the global therapeutic landscape for TGF Beta Receptor Type 1 Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30
The report reviews TGF Beta Receptor Type 1 Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in TGF Beta Receptor Type 1 Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30 targeted therapeutics and enlists all their major and minor projects
The report assesses TGF Beta Receptor Type 1 Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to TGF Beta Receptor Type 1 Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for TGF Beta Receptor Type 1 Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding TGF Beta Receptor Type 1 Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope